This trial is active, not recruiting.

Condition multiple myeloma
Treatment zometa
Phase phase 4
Sponsor Centre Hospitalier Universitaire de Nice
Start date December 2004
End date November 2009
Trial size 350 participants
Trial identifier NCT00733538, IFM-04-01


- Assessment of survival without progression of stage I MM in two groups: arm A: simple survey and arm B: administration of Zoledronate.

- Describe different progression's type noticed and define the prognosis factors of a fast evolution.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model factorial assignment
Masking open label
Primary purpose treatment
(Active Comparator)
patients receiving zometa treatment
patients receiving treatment during their follow-up
(No Intervention)
No treatment, just follow-up

Primary Outcomes

Survival without progress
time frame: every month during 6 years

Secondary Outcomes

predictive factors of a fast evolution of multiple myeloma
time frame: every month during 6 years
Secondary effects of zolédronate
time frame: every month during six years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - stage I multiple myeloma without bones injuries Exclusion Criteria: - abnormal kidney function - VIH infection - Hepatic incapacity - pregnancy - Associate pathology

Additional Information

Official title Stage I Multiple Myeloma Treatment
Principal investigator Jean-Gabriel FUZIBET, PU-PH
Description RATIONAL: Multiple Myeloma in spite of therapy progresses mainly due to stem cell auto transplant, still remain a deadly disease. About 2000 new cases are diagnosed every year in France. The asymptomatic Stage I MM according to Duries and Salmon's staging are usually only watch over and only treated at progression. Zoledronate is a third generation aminobiphosphonate (BP), probably the most powerful among the available compounds which received market clearance authorisation in MM with bone damage. During MM, bone's hyper resorption is premature. Interactions exist between tumor growth and bone lyses. Zoledronate's got a proper antimyeloma's action (induce plasma cells apoptosis). We propose to test the early use of Zoledronate as soon as stage I MM to delay progression. STUDY'S OBJECTIVES: - PRINCIPAL: Assessment of survival without progression stage I MM in two groups: A arm: simple survey and B arm: administration of BP. - SECONDARY: Describe different progression's type noticed (bone/extra bone) and define the prognosis factor of a fast stage I MM evolution (standard factors, cytogenetic 13 deletion, bone's restructuring strains: crosslaps, bone alkaline phosphatase), list side effects. STUDY'S KIND: Multicenter international randomised trial, open labelled, with individual profit. CONTRIBUTING CENTERS: Intergroupe Francophone du Myélome's centers. INCLUSIONS CRITERIA: Asymptomatic stage I MM without bone's lesion on the standard radiographs. STUDY'S MONITORING: After checking inclusion and non inclusion specifications, the patient will be included in the study and randomized (A arm or B arm) before all treatment. The randomisation will be done by center and stratified according to the diagnostic date witch a year or not. - Arm A: simple survey as standard practice. - Arm B: a 15 minutes infusion of Zoledronate every month until progression or a maximum of 18 infusions if no progression. The exams are the one usually defined according to good clinical practices guidelines besides cytogenetic, bone's restructuring strain and serum creatin dosage before each infusion in B arm. STATISTICAL PURPOSES: The minimum number of patients required showing a median survival time increase without progression of 26 months in the control arm and 38 months in the BP arm is about 175 patients in each arm for a 48 months inclusion's period, and a monitoring of 24 months after the last inclusion (i.e. a study's length of 6 years).
Trial information was received from ClinicalTrials.gov and was last updated in March 2012.
Information provided to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice.